Exact Sciences Corp
Symbol: EXAS (NASDAQ)
64.55
▼ (-0.46%) -0.300
Company Description:
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Key Stats
- Today's Open: $64.875
- Today's High: $65.28
- Today's Low: $62.315
- Today's Volume: 1.98M
- Yesterday Close: $64.85
- Yesterday High: $64.925
- Yesterday Low: $63.05
- Yesterday Volume: 2.17M
- Last Min Volume: 4
- Last Min High: $64.55
- Last Min Low: $64.55
- Last Min VWAP: $64.55
Company Profile
- Name: Exact Sciences Corp
- Website: https://www.exactsciences.com
- Listed Date: 2001-01-30
- Location: MADISON, WI
- Market Status: Active
- CIK Number: 0001124140
- SIC Code: 8071
- SIC description: SERVICES-MEDICAL LABORATORIES
- Market Cap: $12.28B
- Round Lot: 100
- Outstanding Shares: 189.32M
- Asset Type: CS
RECENT FILINGS FOR EXAS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-24 | 144 | View |
| 2025-10-10 | 4 | View |
| 2025-10-10 | 4 | View |
| 2025-10-09 | 144 | View |
| 2025-10-09 | 144 | View |
| 2025-09-08 | SCHEDULE 13G/A | View |
| 2025-08-14 | 4 | View |
| 2025-08-13 | 144 | View |
| 2025-08-07 | 4 | View |
| 2025-08-07 | 4 | View |
| 2025-08-06 | 10-Q | View |
| 2025-08-06 | 8-K | View |
| 2025-07-17 | SCHEDULE 13G/A | View |
| 2025-07-16 | 144 | View |
| 2025-07-11 | S-8 POS | View |
| 2025-07-11 | S-8 | View |
| 2025-06-24 | 11-K | View |
| 2025-06-16 | 4 | View |
| 2025-06-16 | 4 | View |
| 2025-06-16 | 4 | View |
Latest News on EXAS